Saturday 17 October 2026 Export EFTR’s income statement to Excel — free account

eFFECTOR Therapeutics, Inc.

0.00 0.00 NaN

Follow EFTR

Alert me

Market cap: $200.0K
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: 2/9
Altman Z: −9.93
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 0.20

Revenue 3.86

Net Income (34.63)

Free Cash Flow (29.19)

Net Debt (6.47)

Current Ratio 1.03

Debt/Equity 22.87

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 62.30%

Next Y EPS Growth 63.50%

Next Y revenue growth —

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

EV/Sales against its own 10 years 41.46%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2021	2022	2023	Q'24
Cash	50	26	18	25
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	53	28	20	26

	2021	2022	2023	Q'24
Payables	1	1	2	2
ST’ Debt	0	19	19	19
Other	3	1	1	1
	4	25	26	26

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	(56.10%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’22	—	2	1	1	4
’21	—	1	0	0	1
’20	26	—	1	—	42

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(7)	—	—	—	—
’23	(8)	(9)	(8)	(6)	(30)
’22	(6)	(4)	(8)	(7)	(26)
’21	(5)	(6)	(9)	(5)	(25)
’20	17	—	21	(21)	14
’20	—	—	—	—	14

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(7)	—	—	—	—
’23	(8)	(9)	(8)	(6)	(30)
’22	(7)	(5)	(8)	(7)	(26)
’22	—	—	—	—	(26)
’21	(4)	(6)	(9)	(5)	(24)
’21	—	—	—	—	(25)
’20	17	—	21	(21)	14

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(2.16)	—	—	—	—
’23	(6.00)	(4.25)	(3.25)	(3.42)	(16.37)
’22	1.75	(4.25)	(5.75)	(5.50)	(13.75)
’21	(113.88)	(95.66)	10.50	11.00	11.00
’20	0.07	—	(132.19)	0.00	133.81
’20	—	—	—	—	0.50

Fiscal quarters ending in the months shown.

Group	Line	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024e
Price, $
Price, $	Low	—	—	—	—	—	—	—	137.50	9.00	8.45	Analyst estimates 2024–2026 Powerpack
	High	—	—	—	—	—	—	—	1,010.50	216.75	37.00
People
People	Employees	—	—	—	—	—	—	2	13	15	14
	Revenue/emp, $m	—	—	—	—	—	—	21.00	0.11	0.24	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	42	1	4	—
	Gross margin, %	—	—	—	—	—	0.00	100.00	100.00	100.00	—
	EBT	—	—	—	—	—	(30)	15	16	(23)	(36)
	EBT margin, %	—	—	—	—	—	0.00	34.67	1,104.76	(637.91)	0.00
	Net income	—	—	—	0	—	(30)	14	16	(23)	(36)
	Depreciation	—	—	—	—	—	0	0	0	0	0
Per share, $
Per share, $	Revenue	—	—	—	—	—	0.00	744.68	2.37	2.16	0.00
	Earnings	—	—	—	—	—	(25.72)	0.01	26.25	(13.75)	(16.37)
	Cash flow	—	—	—	—	—	(2.00)	245.30	(41.19)	(15.72)	(13.51)
	Capex	—	—	—	—	—	0.00	(2.73)	0.94	(0.12)	(0.04)
	Free cash flow	—	—	—	—	—	(2.00)	242.57	(40.26)	(15.84)	(13.56)
	Book value	—	—	—	—	—	(1.00)	(2,344.77)	28.61	2.37	(2.65)
	Shares, m	—	—	—	—	—	14	0	1	2	2
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	0.00	0.00	0.00	—
	P/S	—	—	—	—	—	—	0.00	62.41	4.75	—
	P/B	—	—	—	—	—	—	243,951.29	7.24	4.71	—
	EV/Sales	—	—	—	—	—	—	0.00	46.99	7.75	—
	EV/FCF	—	—	—	—	—	—	0.00	(3.87)	(1.15)	—
Cash, $m
Cash, $m	Operating cash flow	—	—	—	—	—	(28)	14	(25)	(26)	(30)
	Capex	—	—	—	—	—	0	0	1	0	0
	Free cash flow	—	—	—	—	—	(28)	14	(24)	(26)	(30)
Balance, $m
Balance, $m	Working capital	—	—	—	—	—	(15)	8	49	3	(6)
	Total debt	—	—	—	—	—	15	13	19	19	19
	Net debt	—	—	—	—	—	12	(2)	(31)	(7)	1
	Shareholders’ equity	—	—	—	—	—	(14)	(132)	17	4	(6)
Returns, %
Returns, %	ROA	—	—	—	—	—	(557.80)	0.99	44.65	(54.53)	(144.34)
	ROIC	—	—	—	—	—	0.00	0.00	0.00	0.00	0.00
	ROE	—	—	—	—	—	10.18	(0.13)	(27.48)	(214.02)	3,771.56

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2022 · latest quarter Dec 2022

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SEELQ Seelos Therapeutics, Inc.	$700.0K	— (loss-making)	— (loss-making)	+11.90% (above 0%: growing)	n/m	+83.54% (above 0%: growing)	100.00%	(834.84%)	Compare
ATXI Avenue Therapeutics, Inc.	$680.0K	— (loss-making)	— (loss-making)	—	n/m	−169.89% (below 0%: shrinking)	100.00%	0.00%	Compare
SCNI Scinai Immunotherapeutics Ltd. Sponsored ADR	$640.0K	0.0×	— (loss-making)	—	n/m	+51.13% (above 0%: growing)	(228.63%)	(504.50%)	Compare
BDRX Biodexa Pharmaceuticals PLC Unsponsored ADR	$440.0K	— (loss-making)	—	−32.27% (below 0%: shrinking)	+96.36% (above 0%: growing)	−0.17% (below 0%: shrinking)	0.00%	0.00%	Compare
VINC Vincerx Pharma, Inc.	$250.0K	— (loss-making)	—	—	n/m	+42.45% (above 0%: growing)	0.00%	0.00%	Compare
CDT CDT Equity Inc.	$240.0K	— (loss-making)	—	—	n/m	+78.92% (above 0%: growing)	—	0.00%	Compare
EFTR eFFECTOR Therapeutics, Inc.	$200.0K	— (loss-making)	—	+58.08% (above 0%: growing)	n/m	+4.86% (above 0%: growing)	0.00%	0.00%
VRPX Virpax Pharmaceuticals, Inc.	$160.0K	— (loss-making)	—	—	n/m	+4.68% (above 0%: growing)	—	0.00%	Compare
CERO CERo Therapeutics Holdings, Inc.	$140.0K	0.0×	—	—	n/m	+49.65% (above 0%: growing)	—	0.00%	Compare
Median of peers	$345.0K	—	—	—	—	+46.05%	0.00%	0.00%

All 614 Biotechnology stocks →

eFFECTOR Therapeutics, Inc. (EFTR) key facts

eFFECTOR Therapeutics, Inc. (EFTR) is a Biotechnology company in the Healthcare sector.
Return on equity was 3,771.6% and debt-to-equity 22.87.
Its Piotroski F-score is 2 out of 9 and its Altman Z-score is −9.93 (distress zone) for fiscal 2022.

Source: company filings (standardised) and stockrow calculations.